Switch theme
Sign up to access all valuation multiples
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.
2006
155
LTM Revenue $0.7M
LTM EBITDA -$162M
$56.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Adverum Biotechnologies has a last 12-month revenue (LTM) of $0.7M and a last 12-month EBITDA of -$162M.
In the most recent fiscal year, Adverum Biotechnologies achieved revenue of $1.0M and an EBITDA of -$136M.
Adverum Biotechnologies expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Adverum Biotechnologies valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.7M | XXX | $1.0M | XXX | XXX | XXX |
| Gross Profit | $0.7M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$162M | XXX | -$136M | XXX | XXX | XXX |
| EBITDA Margin | -23689% | XXX | -13551% | XXX | XXX | XXX |
| EBIT | -$161M | XXX | -$139M | XXX | XXX | XXX |
| EBIT Margin | -23580% | XXX | -13916% | XXX | XXX | XXX |
| Net Profit | -$156M | XXX | -$131M | XXX | XXX | XXX |
| Net Margin | -22831% | XXX | -13093% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Adverum Biotechnologies's stock price is $2.
Adverum Biotechnologies has current market cap of $46.3M, and EV of $56.4M.
See Adverum Biotechnologies trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $56.4M | $46.3M | XXX | XXX | XXX | XXX | $-6.42 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Adverum Biotechnologies has market cap of $46.3M and EV of $56.4M.
Adverum Biotechnologies's trades at 56.4x EV/Revenue multiple, and -0.4x EV/EBITDA.
Equity research analysts estimate Adverum Biotechnologies's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Adverum Biotechnologies has a P/E ratio of -0.3x.
See valuation multiples for Adverum Biotechnologies and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $46.3M | XXX | $46.3M | XXX | XXX | XXX |
| EV (current) | $56.4M | XXX | $56.4M | XXX | XXX | XXX |
| EV/Revenue | 82.3x | XXX | 56.4x | XXX | XXX | XXX |
| EV/EBITDA | -0.3x | XXX | -0.4x | XXX | XXX | XXX |
| EV/EBIT | -0.3x | XXX | -0.4x | XXX | XXX | XXX |
| EV/Gross Profit | 82.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.3x | XXX | -0.4x | XXX | XXX | XXX |
| EV/FCF | -0.4x | XXX | -0.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAdverum Biotechnologies's last 12 month revenue growth is -66%
Adverum Biotechnologies's revenue per employee in the last FY averaged $6K, while opex per employee averaged $0.9M for the same period.
Adverum Biotechnologies's rule of 40 is -3353% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Adverum Biotechnologies's rule of X is -23854% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Adverum Biotechnologies and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -66% | XXX | -52% | XXX | XXX | XXX |
| EBITDA Margin | -23689% | XXX | -13551% | XXX | XXX | XXX |
| EBITDA Growth | 24% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -3353% | XXX | -13617% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -23854% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $6K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 7704% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 14016% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Adverum Biotechnologies acquired XXX companies to date.
Last acquisition by Adverum Biotechnologies was XXXXXXXX, XXXXX XXXXX XXXXXX . Adverum Biotechnologies acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Adverum Biotechnologies founded? | Adverum Biotechnologies was founded in 2006. |
| Where is Adverum Biotechnologies headquartered? | Adverum Biotechnologies is headquartered in United States of America. |
| How many employees does Adverum Biotechnologies have? | As of today, Adverum Biotechnologies has 155 employees. |
| Who is the CEO of Adverum Biotechnologies? | Adverum Biotechnologies's CEO is Dr. Laurent Fischer, M.D.. |
| Is Adverum Biotechnologies publicy listed? | Yes, Adverum Biotechnologies is a public company listed on NAS. |
| What is the stock symbol of Adverum Biotechnologies? | Adverum Biotechnologies trades under ADVM ticker. |
| When did Adverum Biotechnologies go public? | Adverum Biotechnologies went public in 2014. |
| Who are competitors of Adverum Biotechnologies? | Similar companies to Adverum Biotechnologies include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Adverum Biotechnologies? | Adverum Biotechnologies's current market cap is $46.3M |
| What is the current revenue of Adverum Biotechnologies? | Adverum Biotechnologies's last 12 months revenue is $0.7M. |
| What is the current revenue growth of Adverum Biotechnologies? | Adverum Biotechnologies revenue growth (NTM/LTM) is -66%. |
| What is the current EV/Revenue multiple of Adverum Biotechnologies? | Current revenue multiple of Adverum Biotechnologies is 82.3x. |
| Is Adverum Biotechnologies profitable? | Yes, Adverum Biotechnologies is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Adverum Biotechnologies? | Adverum Biotechnologies's last 12 months EBITDA is -$162M. |
| What is Adverum Biotechnologies's EBITDA margin? | Adverum Biotechnologies's last 12 months EBITDA margin is -23689%. |
| What is the current EV/EBITDA multiple of Adverum Biotechnologies? | Current EBITDA multiple of Adverum Biotechnologies is -0.3x. |
| What is the current FCF of Adverum Biotechnologies? | Adverum Biotechnologies's last 12 months FCF is -$134M. |
| What is Adverum Biotechnologies's FCF margin? | Adverum Biotechnologies's last 12 months FCF margin is -19588%. |
| What is the current EV/FCF multiple of Adverum Biotechnologies? | Current FCF multiple of Adverum Biotechnologies is -0.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
